Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) has shared an announcement.
Shandong Xinhua Pharmaceutical Company Limited has announced the receipt of a Drug Registration Certificate for its Sacubitril Valsartan Sodium tablets from the National Medical Products Administration. This approval marks a significant milestone for the company, enabling it to produce and market this prescription medication, potentially enhancing its market position and offering new opportunities for growth in the pharmaceutical sector.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited is a pharmaceutical company based in China, focusing on the production and distribution of prescription drugs. It operates within the pharmaceutical industry, providing chemical-based medications.
Average Trading Volume: 8,369,606
Technical Sentiment Signal: Buy
Current Market Cap: HK$10.52B
For a thorough assessment of 0719 stock, go to TipRanks’ Stock Analysis page.